Avigen discontinues lead MS drug and considers options after failure
This article was originally published in Scrip
Executive Summary
Avigen has revealed that a Phase IIb study of its lead candidate AV650 (tolperisone HCl), a small molecule for the treatment of spasticity associated with multiple sclerosis (MS), failed to reach its primary endpoint.The company will discontinue further development of the compound as well as assess its strategic options.